VXRT (Vaxart) חוב לטווח קצר להון
This price chart for Vaxart, Inc. (VXRT) illustrates the price action of an asset with a debt-to-equity ratio of 0.00. The business's financial position depends on external investments and test outcomes, as it lacks regular income. Vaxart, Inc. (VXRT) is developing innovative VAAST capsules that replace injections for protection against norovirus and influenza. This unique approach generates scientific interest and confidence among private investors, creating a moderately speculative backdrop.
פילוחים אנליטיים של חברת Vaxart, Inc.
The issuer's credit risk assessment is based on an analysis of the share of liabilities with a maturity of over one year relative to equity, which allows this ratio of short-term debt to equity to reveal hidden leverage, which for Vaxart, Inc. (VXRT) remains minimal due to the priority of government grants and partnership research over commercial loans.